Durect holds follow-on private sale to raise $10M
Pharmaceutical company Durect has struck a deal with Venrock to sell 4.4 million shares of common stock at $2.25 each (a 9 percent discount) to raise $10 million more. Based in Cupertino, Calif., the company, recently valued at $215 million, says it will use the funds for general working capital and late-stage drug development. It is working on treatments for chronic and post-operative pain.
Venrock closed $194 million for late-stage and public investments in health care… Continue Reading
Life sciences briefing: Friday, Sept. 28, 2007
Featured companies: Imalux, Sagent Pharmaceuticals, Sequel Pharmaceuticals, Sinexus, TranS1, U.S. Spinal Technologies
Sagent Pharmaceuticals draws in $53M for injectable generics — Sagent Pharmaceuticals, proving that there’s still life in the apparently lucrative but boring specialty-pharmaceuticals business, raised $53 million in a first funding round. Vivo Ventures led the round for the Schaumburg, Ill., company.
Like other specialty pharmas, Sagent essentially picks up abandoned or cast-off drugs from other companies and tries to make them work in new ways…. Continue Reading